Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.

Yuan, Min; Zhu, Zhongzheng; Mao, Wei; Wang, Hui; Qian, Hong; Wu, Jianguo; Guo, Xianling; Xu, Qing

Yuan, Min; Zhu, Zhongzheng; Mao, Wei; Wang, Hui; Qian, Hong; Wu, Jianguo; Guo, Xianling; Xu, Qing.

Afiliación

Yuan M; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Zhu Z; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Mao W; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Wang H; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Qian H; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Wu J; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Guo X; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Xu Q; Department of Oncology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

Front Oncol ; 11: 796625, 2021.

Article en En | MEDLINE | ID: mdl-35059318

Palabras clave

angiogenesis; anlotinib; anti-PD-1 antibody; immunotherapy; serum cytokine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google